Ovarian Cancer: State of the Art and Perspectives of Clinical Research

Posted On 2021-01-08 14:18:07

Ovarian cancer is composed of three histological subtypes: epithelial (90%), germ cell (5%), and sex cord stromal cell (5%). Epithelial ovarian cancer (EOC) is the most lethal gynecological disorder due to lack of effective early detection strategies. The forthcoming special series focuses on several key elements that are essential for an understanding of this heterogeneous group of malignancies.

In this special series, we tried to review the state of the art of the diagnosis and treatment and share future challenges in ovarian cancer, although several areas warrant further research. We would like to express our sincere gratitude to the authors for their efforts, diligence and commitment.

Ovarian cancer: state of the art and perspectives of clinical research
Stergios Boussios, Nicholas Pavlidis

Review Article
Current practices on genetic testing in ovarian cancer
Florentia Fostira, Marios Papadimitriou, Christos Papadimitriou

Ovarian cancer risk assessment in the era of next-generation sequencing
Renata Colombo Bonadio, Jéssica Rojas Crespo, Maria Del Pilar Estevez-Diz

NOTCH signalling in ovarian cancer angiogenesis
Jose Alejandro Perez-Fidalgo, Belen Ortega, Soraya Simon, Eleftherios Pierre Samartzis, Stergios Boussios

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Stergios Boussios, Michele Moschetta, Peeter Karihtala, Eleftherios P. Samartzis, Matin Sheriff, George Pappas-Gogos, Mehmet Akif Ozturk, Mario Uccello, Afroditi Karathanasi, Michail Tringos, Elie Rassy, Nicholas Pavlidis

Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
Orestis Tsonis, Fani Gkrozou, Konstantinos Vlachos, Minas Paschopoulos, Michail C. Mitsis, Nikolaos Zakynthinakis-Kyriakou, Stergios Boussios, George Pappas-Gogos

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?
John Spiliotis

Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
Elie Rassy, Tarek Assi, Stergios Boussios, Joseph Kattan, Julie Smith-Gagen, Nicholas Pavlidis

Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
Michele Moschetta, Stergios Boussios, Elie Rassy, Eleftherios P. Samartzis, Gabriel Funingana, Mario Uccello

Metformin and ovarian cancer: the evidence
Elina Urpilainen, Ulla Puistola, Stergios Boussios, Peeter Karihtala

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
Eleftherios P. Samartzis, S. Intidhar Labidi-Galy, Michele Moschetta, Mario Uccello, Dimitrios R. Kalaitzopoulos, J. Alejandro Perez-Fidalgo, Stergios Boussios

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
Mario Uccello, Stergios Boussios, Eleftherios P. Samartzis, Michele Moschetta

Current and future immunotherapy approaches in ovarian cancer
Nazım Can Demircan, Stergios Boussios, Tolga Tasci, Mehmet Akif Öztürk

Endometriosis and ovarian cancer risk, an epigenetic connection
Sarah Brunty, Brenda Mitchell, Nadim Bou-Zgheib, Nalini Santanam

The focused issue “Ovarian Cancer: State of the Art and Perspectives of Clinical Research” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Stergios Boussios and Nicholas Pavlidis are serving as the unpaid Guest Editors for the focused issue.